Modified vaccinia Ankara

Modified vaccinia Ankara
Vaccine description
Target	Smallpox, mpox
Vaccine type	Attenuated
Clinical data
Trade names	Imvanex, Imvamune, Jynneos
Other names	MVA
AHFS/Drugs.com	Professional Drug Facts
Routes of; administration	Subcutaneous, Intradermal
ATC code	J07BX (WHO) ;
Legal status
Legal status	CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
ChemSpider	none;

Modified vaccinia Ankara (MVA) is an attenuated (weakened) strain of the vaccinia virus. It is being used as a vaccine (called MVA-BN, brand names: Imvanex in the EU, Imvamune in Canada, and Jynneos in the US) against smallpox and mpox, having fewer side effects than smallpox vaccines derived from other poxviruses.

This third-generation smallpox vaccine has the advantage that it cannot reproduce complete virions in human cells, "the block of the MVA life cycle occurs at the step of virion assembly resulting in assembly of immature virus particles that are not released from the infected cell."

By inserting antigen genes into its genome, modified vaccinia Ankara virus is also used as an experimental viral vector for vaccines against non-poxvirus diseases.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.